Prosztatarák: vizsgálatok itt: Csehország
17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in CsehországA clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Where
- Hradec Králové, Olomouc, Prague
- Életkor
- 18 év and over
- People
- 47 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-512340-32-01 · EU 2024-512340-32-01 - 2. fázisTaking peopleStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Olomouc, Prague
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - 3. fázisTaking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Brno-Stred, Olomouc, Poruba, Prague
- Életkor
- 18 év and over
- People
- 1310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - No phaseTaking peopleCancer Survivors Program
- Where
- Brno
- Életkor
- 18 év and over
- People
- 200
- Run by
- Masaryk Memorial Cancer Institute
See details and how to joinNCT07253987 - 3. fázisTaking peopleA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Liberec I-Stare Mesto, Olomouc, Ostrava, Pardubice, Prague, Prague 4
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - 3. fázisTaking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Brno-Stred, Olomouc, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 1440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - 1/2. fázisTaking peopleStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Where
- Olomouc
- Életkor
- 18 év and over
- People
- 205 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07288359 - 3. fázisTaking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Olomouc, Poruba, Prague 5
- Életkor
- 18 év to 100 év
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00 - 3. fázisTaking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Brno-Stred, Olomouc, Prague, Prague 2
- Életkor
- 18 év and over
- People
- 1314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - 3. fázisTaking peopleThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Brno-Stred, Hradec Králové, Nový Jičín, Olomouc, Prague
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 3. fázisNot yet taking people in CsehországA clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate cancer
- Where
- Brno-Stred, Olomouc, Prague 5
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
See details and how to joinNCT03520478 · EU 2024-515194-10-00 - No phaseTaking peopleThe Effectiveness of Telemedicine Monitoring Prehabilitation in Prostate Cancer Patients Undergoing Radical Prostatectomy
- Where
- Olomouc
- Életkor
- 40 év to 80 év
- People
- 200
- Run by
- University Hospital Olomouc
See details and how to joinNCT06981026 - 4. fázisTaking peopleLong-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Where
- Olomouc, Prague 5
- Életkor
- 18 év to 100 év
- People
- 700 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05803941 · EU 2023-503208-94-00 - 3. fázisTaking peopleTrial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
- Where
- Olomouc
- Életkor
- 18 év and over
- People
- 1210 worldwide
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT03819101 · EU 2023-508072-11-00 - 3. fázisTaking peopleADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
- Where
- Olomouc, Prague
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- UNICANCER
See details and how to joinNCT04916613 · EU 2022-502425-18-00 - 3. fázisTaking peopleIntermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
- Where
- Brno, Olomouc
- Életkor
- 18 év to 100 év
- People
- 1600 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT05974774 · EU 2023-506817-23-01 - No phaseTaking peopleStereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
- Where
- Ostrava
- Életkor
- 18 év and over
- People
- 100
- Run by
- University Hospital Ostrava
See details and how to joinNCT06665932